{"name":"Indivior Inc.","slug":"indivior-inc","ticker":"","exchange":"","domain":"indivior.com","description":"","hq":"Richmond","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":800000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Subutex","genericName":"Buprenorphine Hydrochloride","slug":"buprenorphine-hydrochloride","revenue":800000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1981-01-01","label":"Subutex first approved","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-23","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2027-07-23","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-12-21","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":800000000,"percentOfTotal":100,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Subutex","genericName":"Buprenorphine Hydrochloride","slug":"buprenorphine-hydrochloride","indication":"Acute postoperative pain","status":"marketed","revenue":800000000},{"name":"Subutex, Buprenorphine Hydrochloride, SCH 28444","genericName":"Subutex, Buprenorphine Hydrochloride, SCH 28444","slug":"subutex-buprenorphine-hydrochloride-sch-28444","indication":"Opioid use disorder (maintenance treatment and detoxification)","status":"marketed"},{"name":"Buprenorphine (Subutex)","genericName":"Buprenorphine (Subutex)","slug":"buprenorphine-subutex","indication":"Opioid use disorder (maintenance treatment)","status":"marketed"},{"name":"RBP-6000","genericName":"RBP-6000","slug":"rbp-6000","indication":"Opioid use disorder (maintenance treatment)","status":"phase_3"},{"name":"TM buprenorphine","genericName":"TM buprenorphine","slug":"tm-buprenorphine","indication":"Opioid use disorder (maintenance treatment)","status":"marketed"},{"name":"Transmucosal Buprenorphine","genericName":"Transmucosal Buprenorphine","slug":"transmucosal-buprenorphine","indication":"Opioid use disorder maintenance treatment","status":"marketed"},{"name":"Zubsolv sublingual tablets","genericName":"Zubsolv sublingual tablets","slug":"zubsolv-sublingual-tablets","indication":"Opioid use disorder maintenance treatment","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"Fentanyl - Part A","genericName":"Fentanyl - Part A","slug":"fentanyl-part-a","indication":"Other","status":"phase_1"},{"name":"INDV-2000","genericName":"INDV-2000","slug":"indv-2000","indication":"Other","status":"phase_2"},{"name":"Arbaclofen Placarbil MR Prototype B","genericName":"Arbaclofen Placarbil MR Prototype B","slug":"arbaclofen-placarbil-mr-prototype-b","indication":"Other","status":"phase_1"},{"name":"Suboxone","genericName":"Suboxone","slug":"suboxone","indication":"Other","status":"marketed"},{"name":"XP19986 CR","genericName":"XP19986 CR","slug":"xp19986-cr","indication":"Other","status":"phase_2"},{"name":"Arbaclofen Placarbil MR Prototype A","genericName":"Arbaclofen Placarbil MR Prototype A","slug":"arbaclofen-placarbil-mr-prototype-a","indication":"Other","status":"phase_1"},{"name":"Arbaclofen Placarbil SR","genericName":"Arbaclofen Placarbil SR","slug":"arbaclofen-placarbil-sr","indication":"Other","status":"phase_1"},{"name":"Buprenorphine soluble film","genericName":"Buprenorphine soluble film","slug":"buprenorphine-soluble-film","indication":"Other","status":"phase_2"},{"name":"Fentanyl - Part B","genericName":"Fentanyl - Part B","slug":"fentanyl-part-b","indication":"Other","status":"phase_1"},{"name":"INDV-6001","genericName":"INDV-6001","slug":"indv-6001","indication":"Other","status":"phase_2"},{"name":"Nalorex","genericName":"Nalorex","slug":"nalorex","indication":"Other","status":"phase_1"},{"name":"PERSERIS","genericName":"PERSERIS","slug":"perseris","indication":"Other","status":"marketed"},{"name":"RBP-6300","genericName":"RBP-6300","slug":"rbp-6300","indication":"Other","status":"phase_2"},{"name":"SL Buprenorphine","genericName":"SL Buprenorphine","slug":"sl-buprenorphine","indication":"Other","status":"marketed"},{"name":"Suboxone Sublingual Film","genericName":"Suboxone Sublingual Film","slug":"suboxone-sublingual-film","indication":"Other","status":"marketed"},{"name":"Subutex","genericName":"Subutex","slug":"subutex","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"RBP-7000","genericName":"RBP-7000","slug":"rbp-7000","indication":"Schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"Subutex","genericName":"Buprenorphine Hydrochloride","slug":"buprenorphine-hydrochloride","phase":"marketed","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors.","indications":["Acute postoperative pain","Chronic Pain with Opioid Tolerance","Chronic pain","Opioid dependence","Prevention of opioid abuse"],"catalyst":""},{"name":"Fentanyl - Part A","genericName":"Fentanyl - Part A","slug":"fentanyl-part-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"INDV-2000","genericName":"INDV-2000","slug":"indv-2000","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arbaclofen Placarbil MR Prototype B","genericName":"Arbaclofen Placarbil MR Prototype B","slug":"arbaclofen-placarbil-mr-prototype-b","phase":"phase_1","mechanism":"Arbaclofen placarbil is a prodrug that is converted to arbaclofen, a GABA-B receptor agonist that modulates neurotransmission in the central nervous system.","indications":[],"catalyst":""},{"name":"Suboxone","genericName":"Suboxone","slug":"suboxone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subutex, Buprenorphine Hydrochloride, SCH 28444","genericName":"Subutex, Buprenorphine Hydrochloride, SCH 28444","slug":"subutex-buprenorphine-hydrochloride-sch-28444","phase":"marketed","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder.","indications":["Opioid use disorder (maintenance treatment and detoxification)","Pain management (off-label use in some jurisdictions)"],"catalyst":""},{"name":"XP19986 CR","genericName":"XP19986 CR","slug":"xp19986-cr","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arbaclofen Placarbil MR Prototype A","genericName":"Arbaclofen Placarbil MR Prototype A","slug":"arbaclofen-placarbil-mr-prototype-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arbaclofen Placarbil SR","genericName":"Arbaclofen Placarbil SR","slug":"arbaclofen-placarbil-sr","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buprenorphine (Subutex)","genericName":"Buprenorphine (Subutex)","slug":"buprenorphine-subutex","phase":"marketed","mechanism":"Buprenorphine is a partial opioid agonist that binds to mu-opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a lower risk of overdose compared to full opioid agonists.","indications":["Opioid use disorder (maintenance treatment)","Moderate to severe pain"],"catalyst":""},{"name":"Buprenorphine soluble film","genericName":"Buprenorphine soluble film","slug":"buprenorphine-soluble-film","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fentanyl - Part B","genericName":"Fentanyl - Part B","slug":"fentanyl-part-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"INDV-6001","genericName":"INDV-6001","slug":"indv-6001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nalorex","genericName":"Nalorex","slug":"nalorex","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PERSERIS","genericName":"PERSERIS","slug":"perseris","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RBP-6000","genericName":"RBP-6000","slug":"rbp-6000","phase":"phase_3","mechanism":"RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods.","indications":["Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"RBP-6300","genericName":"RBP-6300","slug":"rbp-6300","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RBP-7000","genericName":"RBP-7000","slug":"rbp-7000","phase":"phase_3","mechanism":"RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period.","indications":["Schizophrenia","Schizoaffective disorder"],"catalyst":""},{"name":"SL Buprenorphine","genericName":"SL Buprenorphine","slug":"sl-buprenorphine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Suboxone Sublingual Film","genericName":"Suboxone Sublingual Film","slug":"suboxone-sublingual-film","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subutex","genericName":"Subutex","slug":"subutex","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TM buprenorphine","genericName":"TM buprenorphine","slug":"tm-buprenorphine","phase":"marketed","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","indications":["Opioid use disorder (maintenance treatment)","Moderate to severe pain"],"catalyst":""},{"name":"Transmucosal Buprenorphine","genericName":"Transmucosal Buprenorphine","slug":"transmucosal-buprenorphine","phase":"marketed","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","indications":["Opioid use disorder maintenance treatment","Acute pain management","Chronic pain"],"catalyst":""},{"name":"Zubsolv sublingual tablets","genericName":"Zubsolv sublingual tablets","slug":"zubsolv-sublingual-tablets","phase":"marketed","mechanism":"Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder.","indications":["Opioid use disorder maintenance treatment"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5","date":"2026-04-06","type":"pipeline","source":"TradingView","summary":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - TradingView","headline":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE0wT29WcEZiOTFXdi1XRFJ6UFoyN2RUdnVzWmJ4cVJyUG9ndmxQcFQzakw0UXVqajF5X2Q0VFRSNEF6eUluYVVpLXJ5a1RBVzB6ckUwUnpRNGtCeHNDdmRlZEdQRU5ic3hSbDdiM3NR?oc=5","date":"2026-04-04","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan","headline":"If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE42emdjdC1KSFNCUXFIYjc2VXZoNlY5VzdZaW02U0xTY21MaGpHUDI2VXJtcFpTWDUtRE9JclpmUG9VdFpybUZjSEtlQ1c2NEVzeE5NNVIxWE04cXhCSVE?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Indivior Pharmaceuticals Inc. R (E7P.F) Company Profile & Facts - Yahoo! Finance Canada","headline":"Indivior Pharmaceuticals Inc. R (E7P.F) Company Profile & Facts - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE44UFZYdDdWLXRxX2Y5TE1INjhvRnhJODFHcW0zeG9xVXhWSlptZzE3Y21yYUlZc0ZoRUdSaGF3bmFEa2tEUEZ5OWNVYkdFVTZualAyNk1MT3pTa0Z0SDVZ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"INDV Stock Price, Quote & Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill","headline":"INDV Stock Price, Quote & Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRTVrNFBlX3ZXVGJsY0dFR05hVjR6Q1o1bjZrcElrMnNzRUFIYXpLSHpYNnJBWmEzU3VCOVJTWTY4OVdzME5EaEdzNms0bzBNMlJNbTJPY3F3ZzBGZFdFZl9OVUplVWNlS0lwV3dUMlpiODBQVWFIclZDME03MEp3ajlCck5jT1pKRWlpQlNhN2kzRHYzWmVncHVlTEtZc0VINGtFNXF2ME1scTlJTTU3QmJELVpOWVc5VXBIdTZENktDUUU?oc=5","date":"2026-03-27","type":"deal","source":"Stock Titan","summary":"Indivior (INDV) posts 2025 growth, SUBLOCADE gains and $400M buyback in 2026 proxy - Stock Titan","headline":"Indivior (INDV) posts 2025 growth, SUBLOCADE gains and $400M buyback in 2026 proxy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQN1lnUVRfWFhhNmNEamQtdHhrVTFKVE9QVTRmYk5hUS15bE83NlpoM3FMeEZudkZsbTlsbHZLUy1rWXhFS05RU3NxWkxMeUg2VExNZXVVbU43YjUzSkluUmJGNDdhTWhaeTZRR0I0MlQzMDZkSERCSl9LYlFVS1BjdXpfN0VmNTlBOTZLOHRYVE5paWdKZTBZTU9XUzB3ZWZDekNSQWN3TXZ3aWpVdUhSamZVT0VwaE1ZY01KSVgzRQ?oc=5","date":"2026-03-26","type":"pipeline","source":"AD HOC NEWS","summary":"Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus - AD HOC NEWS","headline":"Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPQmViSGNIMXhiUFBqVE9lbTQ0cUpfRlk3R1d4N3RuTE1aTmJVNi0yMDFqNzdrWEM0Z05vZld1TGk0VkFyaWc3aDBxMnZGZWtxcjNubk0tQkdESzBLYkhFLURHbjE3REtnSWp6UTZmZEZ5Qm1saEZMNXZVb2Q0aGNVZ3lkdXJfRndpdWJfbnVFelJuT2NFMXZDVzBFQUI0UTdubXFYRFo3M2xjcFRMNnhkWVJ3SlhWSkRLeHpFcg?oc=5","date":"2026-03-25","type":"pipeline","source":"Seeking Alpha","summary":"Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha","headline":"Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQVy1HRVBjbVhXYUYtMnNzc0h1NG1QeUFEYjN6UkZpQzB5ajhJcnpqMnp4bXRUMjFpZTZSWkl1Si1uTDJlYWRsX3FEUVFLMmJSRklpSUVISWhWeWpkaFN4ZDhqMURTdGZoU2hzaHVGUGkzNWxUVXZ4MEgxVi1ZYUZfRHVkeGtGalJpZ25BZWlXeU1CODRGUjZwOWpra1BGTkxjUEZZRlE2R1duOGV2S0ljdzVzeDJmMmU2UVdlbUxCUEs0Nm92OXVGNGE1VzBZQQ?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Indivior Announces Proposed Convertible Senior Notes Offering - GlobeNewswire","headline":"Indivior Announces Proposed Convertible Senior Notes Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPbXpONlBIdFd0QkxDR1ZFZ0xRY0VRUUZYTWNUN09odXlod2Z6YXNIdTJFekRXUDZjSGg2VjNfOEFYTGJDS2tETlVUbXAxQTVoSWdaZXNpaWM2RFhxQW4xby1ZSWV2VHZlX3ZQRjVCTHNKNUg1MEJRWEVkTFJOa3NHTQ?oc=5","date":"2026-03-12","type":"pipeline","source":"Yahoo Finance","summary":"Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - Yahoo Finance","headline":"Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOXzl1MFdQa2hpa1VVczNNTGhnRW5WT2EtZ1gxcEc2Zmdmd2NKQWlOcGc5RmhPS1h1QmlhOUEzem0zUzBGWVdjSkNjaGVvSHRvdGM1OXNJMUE3VGlWYlhMSnZ5NjZDTUk4ajN5WVRyUDJWNENmdEFRSDRrcmJtU19ublYtSjBCYkUtRmQ1d0xsN1VUeDRQcGVLSWo2WlQyVW1jWHR1Uy1EVFM0Y3RaNUlVV05pM1Z0enVHMHhtWHNYQTcxMms?oc=5","date":"2025-10-01","type":"pipeline","source":"prnewswire.com","summary":"Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation - prnewswire.com","headline":"Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNc2ZUTzV2cDJSSkFKU3JpUW1LOXBaYTZnX01zaHJmVG03RURSX0FYeHNFaWVrVk9sWWNJUm14elV2YkpVcDBoeV9xb2FGY0JRa2E0OVBDX2R6Y1ZKcHVxNHFhLUZJMl9wTlp4UEQ4U29SWk56TUNuc0IxX0JuRUN5X3dwdm54bkJmRzhSUE04NEptbHFFU2o4NTAtRThiQQ?oc=5","date":"2025-09-30","type":"pipeline","source":"Times Union","summary":"AG settles with pharma company Indivior over opioid overdose drug - Times Union","headline":"AG settles with pharma company Indivior over opioid overdose drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPUXN5anJBbzgwUnlrZ1FDRnd3OFh3aVlONTgtdVdOR2VjLXpHTkVSRm9KVXExX1p0MjJ0T3VLaWs3MFZFZnJiV3dZZ2swWmhmQ3h6Rmk0ZHlKUzhLN3lOempZNnZxN2xJM2hwWkx4VkhzdndiZ0ZvaHNwRzQ5Wl9FYkNWdGxYbVNWTlIwb1lGTXY1LUwwbmpLLUhUOG9PaUowNHpHZE54YmtrZTlqSHZoTnhDa2tsSjl0NURFN3N3?oc=5","date":"2025-08-27","type":"trial","source":"Fierce Pharma","summary":"Indivior slims head count, weighs Opvee divesture in first phase of multiyear restructuring plan - Fierce Pharma","headline":"Indivior slims head count, weighs Opvee divesture in first phase of multiyear restructuring plan","sentiment":"neutral"}],"patents":[{"drugName":"Subutex","drugSlug":"buprenorphine-hydrochloride","patentNumber":"8147866","type":"Formulation","expiryDate":"2027-07-23","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine-hydrochloride","patentNumber":"9655843","type":"Formulation","expiryDate":"2027-07-23","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine-hydrochloride","patentNumber":"9901539","type":"Method of Use","expiryDate":"2032-12-21","territory":"US","annualRevenue":800000000,"genericFilings":[]}],"drugCount":24,"phaseCounts":{"marketed":10,"phase_1":6,"phase_2":6,"phase_3":2},"enrichmentLevel":0,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}